Browse CD40

Summary
SymbolCD40
NameCD40 molecule, TNF receptor superfamily member 5
Aliases Bp50; TNFRSF5; tumor necrosis factor receptor superfamily, member 5; CDW40; B cell surface antigen CD40; B c ......
Chromosomal Location20q12-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform I: Cell membrane; Single-pass type I membrane protein.; SUBCELLULAR LOCATION: Isoform II: Secreted.
Domain PF00020 TNFR/NGFR cysteine-rich region
Function

Receptor for TNFSF5/CD40LG. Transduces TRAF6- and MAP3K8-mediated signals that activate ERK in macrophages and B cells, leading to induction of immunoglobulin secretion.

> Gene Ontology
 
Biological Process GO:0000018 regulation of DNA recombination
GO:0001562 response to protozoan
GO:0001819 positive regulation of cytokine production
GO:0002200 somatic diversification of immune receptors
GO:0002204 somatic recombination of immunoglobulin genes involved in immune response
GO:0002208 somatic diversification of immunoglobulins involved in immune response
GO:0002237 response to molecule of bacterial origin
GO:0002250 adaptive immune response
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002312 B cell activation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002377 immunoglobulin production
GO:0002381 immunoglobulin production involved in immunoglobulin mediated immune response
GO:0002440 production of molecular mediator of immune response
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002562 somatic diversification of immune receptors via germline recombination within a single locus
GO:0002637 regulation of immunoglobulin production
GO:0002639 positive regulation of immunoglobulin production
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002700 regulation of production of molecular mediator of immune response
GO:0002702 positive regulation of production of molecular mediator of immune response
GO:0002703 regulation of leukocyte mediated immunity
GO:0002705 positive regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002708 positive regulation of lymphocyte mediated immunity
GO:0002712 regulation of B cell mediated immunity
GO:0002714 positive regulation of B cell mediated immunity
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0002819 regulation of adaptive immune response
GO:0002821 positive regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002889 regulation of immunoglobulin mediated immune response
GO:0002891 positive regulation of immunoglobulin mediated immune response
GO:0006310 DNA recombination
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0007259 JAK-STAT cascade
GO:0007260 tyrosine phosphorylation of STAT protein
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0009306 protein secretion
GO:0009612 response to mechanical stimulus
GO:0009615 response to virus
GO:0016064 immunoglobulin mediated immune response
GO:0016444 somatic cell DNA recombination
GO:0016445 somatic diversification of immunoglobulins
GO:0016447 somatic recombination of immunoglobulin gene segments
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0019724 B cell mediated immunity
GO:0030168 platelet activation
GO:0030888 regulation of B cell proliferation
GO:0030890 positive regulation of B cell proliferation
GO:0032496 response to lipopolysaccharide
GO:0032615 interleukin-12 production
GO:0032655 regulation of interleukin-12 production
GO:0032735 positive regulation of interleukin-12 production
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0033209 tumor necrosis factor-mediated signaling pathway
GO:0033674 positive regulation of kinase activity
GO:0034612 response to tumor necrosis factor
GO:0042100 B cell proliferation
GO:0042113 B cell activation
GO:0042508 tyrosine phosphorylation of Stat1 protein
GO:0042509 regulation of tyrosine phosphorylation of STAT protein
GO:0042510 regulation of tyrosine phosphorylation of Stat1 protein
GO:0042511 positive regulation of tyrosine phosphorylation of Stat1 protein
GO:0042531 positive regulation of tyrosine phosphorylation of STAT protein
GO:0042832 defense response to protozoan
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043405 regulation of MAP kinase activity
GO:0043406 positive regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0043491 protein kinase B signaling
GO:0045190 isotype switching
GO:0045191 regulation of isotype switching
GO:0045830 positive regulation of isotype switching
GO:0045860 positive regulation of protein kinase activity
GO:0045911 positive regulation of DNA recombination
GO:0046425 regulation of JAK-STAT cascade
GO:0046427 positive regulation of JAK-STAT cascade
GO:0046651 lymphocyte proliferation
GO:0048291 isotype switching to IgG isotypes
GO:0048302 regulation of isotype switching to IgG isotypes
GO:0048304 positive regulation of isotype switching to IgG isotypes
GO:0048305 immunoglobulin secretion
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050708 regulation of protein secretion
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0050817 coagulation
GO:0050864 regulation of B cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050871 positive regulation of B cell activation
GO:0050878 regulation of body fluid levels
GO:0051023 regulation of immunoglobulin secretion
GO:0051052 regulation of DNA metabolic process
GO:0051054 positive regulation of DNA metabolic process
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051092 positive regulation of NF-kappaB transcription factor activity
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051607 defense response to virus
GO:0055074 calcium ion homeostasis
GO:0070528 protein kinase C signaling
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0071214 cellular response to abiotic stimulus
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071260 cellular response to mechanical stimulus
GO:0071356 cellular response to tumor necrosis factor
GO:0071396 cellular response to lipid
GO:0071496 cellular response to external stimulus
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072577 endothelial cell apoptotic process
GO:0090036 regulation of protein kinase C signaling
GO:0090037 positive regulation of protein kinase C signaling
GO:0097696 STAT cascade
GO:0098542 defense response to other organism
GO:1904019 epithelial cell apoptotic process
GO:1904035 regulation of epithelial cell apoptotic process
GO:1904037 positive regulation of epithelial cell apoptotic process
GO:1904892 regulation of STAT cascade
GO:1904894 positive regulation of STAT cascade
GO:2000351 regulation of endothelial cell apoptotic process
GO:2000353 positive regulation of endothelial cell apoptotic process
Molecular Function GO:0003823 antigen binding
GO:0005031 tumor necrosis factor-activated receptor activity
GO:0005035 death receptor activity
GO:0031625 ubiquitin protein ligase binding
GO:0044389 ubiquitin-like protein ligase binding
Cellular Component GO:0009897 external side of plasma membrane
GO:0035631 CD40 receptor complex
GO:0043235 receptor complex
GO:0098552 side of membrane
GO:0098802 plasma membrane receptor complex
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04064 NF-kappa B signaling pathway
hsa04514 Cell adhesion molecules (CAMs)
hsa04620 Toll-like receptor signaling pathway
hsa04672 Intestinal immune network for IgA production
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-5676594: TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
R-HSA-5668541: TNFR2 non-canonical NF-kB pathway
Summary
SymbolCD40
NameCD40 molecule, TNF receptor superfamily member 5
Aliases Bp50; TNFRSF5; tumor necrosis factor receptor superfamily, member 5; CDW40; B cell surface antigen CD40; B c ......
Chromosomal Location20q12-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CD40 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CD40 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27217585Pancreatic Ductal AdenocarcinomaPromote immunity (infiltration)Agonistic CD40 mAb promotes stromal degradation and, in combination with chemotherapy, drives T cell infiltration and de novo responses against tumors, rendering resistant tumors susceptible to current immunotherapies.
26917236GliomaPromote immunity (infiltration)In vitro, we demonstrated direct antitumor effects of an anti-CD40 agonistic monoclonal antibody (FGK45) against the cell lines. Increases in apoptosis and CD4(+) and CD8(+) T cell infiltration were observed in the bRiTs-G3 model after FGK45 treatment.
26141620MelanomaPromote immunity (T cell function)We found that the combination of agonistic anti-CD40 + IL2/anti-IL2 complexes (IL2cx) + IL12Fc was a distinctively effective treatment with respect to priming protective, tumor-specific immunity and eradicating tumors at advanced disease stage.
25351848Colon CarcinomaInhibit immunity (T cell function)In addition, we demonstrated that the CD40:CD40L cross-talk between the two cell populations is responsible for the instauration of a proinflammatory microenvironment and for the increase in the production of mediators that can further support MDSC mobilization and tumor growth.
27622331Colorectal CarcinomaPromote immunity (T cell function)These myeloid cells are phenotypically similar to inducible nitric oxide synthase (NOS2)- and tumor necrosis factor (TNF)-producing dendritic cells (DC), or Tip-DCs. Tumor elimination via NOS2 required the CD40-CD40L pathway. We also uncovered a strong correlation between survival of colorectal cancer patients and NOS2, CD40, and TNF expression in their tumors.
24556719Lung CarcinomaPromote immunityCombined anti-CD40 and anti-IL-23 monoclonal antibody therapy effectively suppresses tumor growth and metastases. Interestingly, in the experimental lung metastases tumor models, we observed that intracellular IL-23 production was specifically restricted to MHC-II(hi)CD11c(+)CD11b(+) cells.
19380767MesotheliomaPromote immunity (T cell function)Because local imiquimod treatment did not induce significant CD4 T cell responses, we investigated the efficacy of combining imiquimod with agonistic CD40 Ab (as a surrogate for CD4 T cell help). Combination of locally delivered imiquimod with systemic anti-CD40 immunotherapy not only significantly enhanced the local antitumor response, with 30% complete resolution, but it was also effective at significantly retarding growth of distal tumor.
23619361Acute Myeloid LeukemiaPromote immunity (T cell function)CD40 ligation reverses T cell tolerance in acute myeloid leukemia. Administration of agonistic anti-CD40 Ab to activate host APCs enhanced accumulation of functional T cells and prolonged survival.
21282461Bladder CarcinomaPromote immunityThe immunostimulatory effects of CD40 ligation on malignant cells can be switched to apoptosis upon disruption of survival signals transduced by the binding of the adaptor protein TRAF6 to CD40.
16680149Breast Carcinoma; Renal Cell Carcinoma; Colon Carcinoma; Lung CarcinomaPromote immunity (T cell function)Here we show that induction of tumor-cell apoptosis by an agonistic monoclonal antibody to DR5, the apoptosis-inducing receptor for TNF-related apoptosis-inducing ligand (TRAIL), combined with T-cell activation by agonistic monoclonal antibodies to the costimulatory molecules CD40 and CD137, potently and rapidly stimulated tumor-specific effector CD8+ T cells capable of eradicating preestablished tumors. This combination therapy of three monoclonal antibodies (trimAb) rapidly induced tumor-specific CD8+ T cells producing interferon (IFN)-gamma in the tumor-draining lymph node, consistent with a crucial requirement for CD8+ T cells and IFN-gamma in the tumor rejection process.
16565324NeuroblastomaPromote immunityIn vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages.
23649004NeuroblastomaPromote immunityIn the Neuro2a model, treatment of established tumor with anti-4-1BB, anti-CD40, or anti-CTLA-4 mAb results in tumor regression and long-term survival in 40% to 60% of mice. This is dependent on natural killer (NK) and CD8(+) T cells and is associated with tumor CD8(+) lymphocyte infiltrate. These data suggest that the combination of antigen and costimulatory mAb may provide effective immunotherapy against neuroblastoma and may be of particular use in the minimal residual disease setting.
24778163Bladder CarcinomaPromote immunityDespite the lack of a slow-release system, local anti-CD40 therapy was dependent on tumor antigen at the injection site for clearance of distant tumors. To summarize, local low-dose administration of anti-CD40 antibody mediates antitumor effects in murine models with reduced toxicity and may represent an attractive treatment alternative in the clinic.
19201847LymphomaPromote immunitySeveral receptor-ligand pairs are reciprocally expressed on Mphi and L5178Y cell membranes and can be potentially involved in Mphi priming. Of these, the CD40-CD154 pair played the most important role, as blocking the interaction of these molecules substantially reduced in vitro Mphi priming. These results suggest that contact with certain tumor cells via CD40, NKG2D, and CD18 molecules on the Mphi may facilitate Mphi-mediated antitumor immune surveillance.
17982058Pancreatic CarcinomaPromote immunityIn this report, we show that the conditioning of tumor-bearing RIP1-Tag4 mice with agonistic anti-CD40 Ab induces extensive expansion of naive epitope I-specific TCR transgenic (TCR-I) T cells in this tolerogenic environment and delays their loss from the host. In addition, functional TCR-I T cells intensively infiltrate pancreatic tumors, resulting in increased survival of RIP1-Tag4 mice.
25024386lymphomaPromote immunityThe dependence on FcγRIIB for immunostimulatory activity was not absolute, however, because when anti-CD40 mAbs were administered systemically with the TLR3 agonist polyinosinic:polycytidylic acid or were given subcutaneously, activatory FcγR could also provide cross-linking.
29634944Pancreatic CarcinomaPromote immunity (T cell function); increase the efficacy of immunotherapyCD40 activation plays a critical role in generating T cell immunity, by activating dendritic cells, and converting cold tumors to hot.
29594038Lung CarcinomaPromote immunityOverall, 60% of mice treated with SRBs showed complete tumor regression during the observation period, compared to 10% for cohorts administered with anti-CD40 mAbs, but no SRB.
29576376Pancreatic CarcinomaPromote immunityHere we determined characteristics of nine hCD40 mAbs engaging epitopes throughout the CD40 extracellular region expressed as varying isotypes.
21540234Renal Cell CarcinomaPromote immunity (T cell function); essential for immunotherapyNotably, the AZD8055/αCD40-induced antitumor response was abolished in IFN-γ(-/-) and CD40(-/-) mice, establishing the reliance of the combination therapy on host IFN-γ and CD40 expression.
21514665B16 Malignant MelanomaPromote immunityImmunostimulatory therapies that activate immune response pathways are of great interest for overcoming the immunosuppression present in advanced tumors. Agonistic anti-CD40 antibodies and CpG oligonucleotides have previously demonstrated potent, synergistic anti-tumor effects, but their clinical use even as monotherapies is hampered by dose-limiting inflammatory toxicity provoked upon systemic exposure.
21436454Pancreatic Ductal Adenocarcinoma; Pancreatic CarcinomaPromote immunity (T cell function & infiltration); essential for immunotherapyBecause CD40 activation can reverse immune suppression and drive antitumor T cell responses, we tested the combination of an agonist CD40 antibody with gemcitabine chemotherapy in a small cohort of patients with surgically incurable PDA and observed tumor regressions in some patients. CD40-activated macrophages rapidly infiltrated tumors, became tumoricidal, and facilitated the depletion of tumor stroma.
18537185Hepatocellular CarcinomaPromote immunityCD40/CD40L interaction is essential for DC activation and induction of antigen-specific T-cells. Ad-CD40L transduction exerted CD40/CD40L interactions between DCs, increasing DC immunostimulation with up-regulation of CD80/CD86- and interleukin-12 (IL-12) expression.
16103104B-Cell Non-Hodgkin LymphomaPromote immunityCertain novel immunomodulatory mAbs such as anti-CD40 have shown significant activity in preclinical models. We therefore assessed the efficacy of combining anti-CD40 mAb, known to elicit CTL responses against murine lymphoma models with the commonly used cytotoxic drug, cyclophosphamide.
29467128Gastrointestinal Stromal TumorPromote immunityHere, we showed that ligation of CD40 using an agonistic antibody (anti-CD40) activated tumor-associated macrophages (TAMs) in vivo in a knock-in mouse model of GIST harboring a germline mutation in Kit exon 11. CD40 ligation did not have a direct inhibitory effect on human GIST cells. Our findings provide the rationale for combining anti-CD40 and tyrosine kinase inhibition to treat human GIST.
28062694MelanomaPromote immunityUsing the mouse GD2+B78 melanoma model, we show that anti-CD40/CpG treatment led to upregulation of T cell activation markers in draining lymph nodes.
20628372MesotheliomaPromote immunityCD40-activated B cells contribute to mesothelioma tumor regression. In this study, we show that injecting lower doses of anti-CD40 Ab directly into the tumor bed avoided toxic side effects and prolonged survival in 60% of mice, with most cured. Adoptive transfer of tumor antigen-experienced, CD40-activated B cells, or their immunoglobulin products, which recognized autoantigens on mesothelioma cells, protected against tumor challenge.
29844122Pancreatic Ductal AdenocarcinomaPromote immunityRadiotherapy and CD40 activation separately augment immunity to checkpoint blockade in cancer. The combination of an agonist αCD40 antibody, RT, and dual ICB eradicated irradiated and unirradiated (i.e. abscopal) tumors, generating long-term immunity.
21852502lymphomaPromote immunity. Direct comparison of mAbs to CD40 enhanced for activating FcgammaR binding, hence capable of cytotoxicity, or for inhibitory FcgammaRIIB binding, revealed that enhancing FcgammaRIIB binding conferred immunostimulatory activity and considerably greater anti-tumor responses.
16920987pancreatic carcinomaPromote immunityMedium conditioned by human pancreatic carcinoma cells inhibited iMo-DC proliferation, expression of costimulatory molecules (CD80 and CD40) and of HLA-DR, and functional activity as assessed by MLR and IL-12p70 production. iMo-DC generated from pancreatic carcinoma patients in advanced stages of the disease similarly showed decreased levels of HLA-DR expression and reduced ability to stimulate MLR in response to CD40L and IFN-gamma.
16917008Multiple myeloma(IgA, IgD, IgE, IgM, IgG)Promote immunityWe found that patient-derived MoDCs are phenotypically and functionally defective. Compared with their normal counterparts, patient-derived, mature MoDCs expressed significantly lower levels of CD1a, CD40, CD80, and HLA-DR and were poor at activating alloreactive T cells, presenting recall antigen, and activating autologous antigen- and myeloma-specific T cells.
Summary
SymbolCD40
NameCD40 molecule, TNF receptor superfamily member 5
Aliases Bp50; TNFRSF5; tumor necrosis factor receptor superfamily, member 5; CDW40; B cell surface antigen CD40; B c ......
Chromosomal Location20q12-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CD40 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCD40
NameCD40 molecule, TNF receptor superfamily member 5
Aliases Bp50; TNFRSF5; tumor necrosis factor receptor superfamily, member 5; CDW40; B cell surface antigen CD40; B c ......
Chromosomal Location20q12-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CD40 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0220.962
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.180.913
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0910.94
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4050.317
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0040.998
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.9130.615
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3470.419
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5190.669
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1830.889
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.540.75
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.990.7
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.070.62
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CD40 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCD40
NameCD40 molecule, TNF receptor superfamily member 5
Aliases Bp50; TNFRSF5; tumor necrosis factor receptor superfamily, member 5; CDW40; B cell surface antigen CD40; B c ......
Chromosomal Location20q12-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD40. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCD40
NameCD40 molecule, TNF receptor superfamily member 5
Aliases Bp50; TNFRSF5; tumor necrosis factor receptor superfamily, member 5; CDW40; B cell surface antigen CD40; B c ......
Chromosomal Location20q12-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD40. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD40.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCD40
NameCD40 molecule, TNF receptor superfamily member 5
Aliases Bp50; TNFRSF5; tumor necrosis factor receptor superfamily, member 5; CDW40; B cell surface antigen CD40; B c ......
Chromosomal Location20q12-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD40. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCD40
NameCD40 molecule, TNF receptor superfamily member 5
Aliases Bp50; TNFRSF5; tumor necrosis factor receptor superfamily, member 5; CDW40; B cell surface antigen CD40; B c ......
Chromosomal Location20q12-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CD40 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCD40
NameCD40 molecule, TNF receptor superfamily member 5
Aliases Bp50; TNFRSF5; tumor necrosis factor receptor superfamily, member 5; CDW40; B cell surface antigen CD40; B c ......
Chromosomal Location20q12-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CD40 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCD40
NameCD40 molecule, TNF receptor superfamily member 5
Aliases Bp50; TNFRSF5; tumor necrosis factor receptor superfamily, member 5; CDW40; B cell surface antigen CD40; B c ......
Chromosomal Location20q12-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CD40 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CD40.
ID Name Drug Type Targets #Targets
DB06360LucatumumabSmall MoleculeCD401
DB12589DacetuzumabBiotechCD401